Neurosteer

Neurosteer® has developed a solution for the early detection and more effective treatment of a variety of neurological disorders. It consists of a medical-grade wearable device and cloud-based system that provides real-time monitoring and assessment of brain activity. The company’s current focus is on delivering objective biomarkers that identify the early onset of Parkinson’s, Alzheimer’s, dementia and epilepsy.

Neurosteer uses an adhesive forehead strip connected to a pocket-sized device that wirelessly transmits sensor data to the cloud for proprietary signal processing. Advanced algorithms then decompose the single EEG channel into 100+ individual components for real-time analysis and display on a Web-based dashboard. The result is more affordable screening, continuous patient monitoring, and optimized neurostimulation and drug selection, leading to improved neurological treatment and outcome of clinical trials.

Neurosteer headquartered in New York, New York, United States, North America, operates in the Medical Device, Neuroscience sector. The company focuses on Medical Device and has secured $158.0M in funding across 24 round(s). With a team of 11-50 employees, Neurosteer is actively contributing to advancements in Medical Device. Their latest funding round, Seed Round - Neurosteer, raised $2.0M. Discover more about their projects, partnerships, and impact on our platform.